Miura Shuhei, Iba Yutaka, Mukawa Kei, Nakanishi Keitaro, Mizuno Takakimi, Arihara Ayaka, Shibata Tsuyoshi, Nakazawa Junji, Nakajima Tomohiro, Kawaharada Nobuyoshi
Department of Cardiovascular Surgery, Sapporo Medical University, Sapporo, Japan.
JTCVS Open. 2024 May 28;20:1-13. doi: 10.1016/j.xjon.2024.05.009. eCollection 2024 Aug.
This study aimed to evaluate the long-term outcomes of surgical strategies for communicating DeBakey IIIb chronic dissecting aortic aneurysm, considering the optimal primary surgical repair to prevent aortic events.
From 2002 to 2021, 101 patients with communicating DeBakey IIIb chronic dissecting aortic aneurysm who underwent surgical repair were categorized based on the primary surgical repair: 1-stage repair of thoracoabdominal aortic aneurysm (TAAAR) (n = 22) or staged repair, such as descending thoracic aneurysm repair (DTAR) (n = 43) or total arch replacement with elephant trunk implantation (TARET) (n = 25), and thoracic endovascular aortic repair (TEVAR) (n = 11). Early and late postoperative outcomes were compared among the groups.
Early outcomes for TAAAR, DTAR, TARET, and TEVAR were associated with the incidence of stroke (9.1% vs 0% vs 4.0% vs 9.1%, respectively), spinal cord injury (13.6% vs 4.7% vs 8.0% vs 0%, respectively), and in-hospital mortality (9.1% vs 2.3% vs 0% vs 9.1%, respectively). During follow-up, the 10-year overall survival and 7-year aortic event-free rates for TAAAR, DTAR, TARET, and TEVAR were 61.8%, 71.6%, 21.5%, and 26.5% and 93.8%, 84.3%, 74.4%, and 51.4%, respectively. TAAAR had significantly higher overall survival ( = .05) and aortic event-free rates ( = .03) than TEVAR. TARET (hazard ratio, 2.27; < .01) and TEVAR (hazard ratio, 3.40; < .01) were independently associated with the incidence of aortic events during follow-up.
Considering the optimal primary surgical repair based on long-term outcomes, TEVAR was not a durable treatment option. Patient-specific TAAAR or DTAR should be considered rather than defaulting to minimally invasive primary repairs for all patients with communicating DeBakey IIIb chronic dissecting aortic aneurysm.
本研究旨在评估治疗交通性DeBakey IIIb型慢性主动脉夹层动脉瘤手术策略的长期疗效,同时考虑最佳的一期手术修复以预防主动脉相关事件。
2002年至2021年期间,101例行手术修复的交通性DeBakey IIIb型慢性主动脉夹层动脉瘤患者根据一期手术修复方式进行分类:胸腹主动脉瘤一期修复术(TAAAR)(n = 22)、分期修复,如下降胸主动脉瘤修复术(DTAR)(n = 43)或带象鼻支架植入的全弓置换术(TARET)(n = 25)以及胸主动脉腔内修复术(TEVAR)(n = 11)。比较各组术后早期和晚期疗效。
TAAAR、DTAR、TARET和TEVAR的早期疗效与卒中发生率(分别为9.1%、0%、4.0%和9.1%)、脊髓损伤发生率(分别为13.6%、4.7%、8.0%和0%)及住院死亡率(分别为9.1%、2.3%、0%和9.1%)相关。随访期间,TAAAR、DTAR、TARET和TEVAR的10年总生存率及7年无主动脉事件生存率分别为61.8%、71.6%、21.5%、26.5%和93.8%、84.3%、74.4%、51.4%。TAAAR的总生存率(P = 0.05)和无主动脉事件生存率(P = 0.03)显著高于TEVAR。TARET(风险比,2.27;P < 0.01)和TEVAR(风险比,3.40;P < 0.01)与随访期间主动脉事件的发生率独立相关。
基于长期疗效考虑最佳的一期手术修复方式,TEVAR并非持久的治疗选择。对于所有交通性DeBakey IIIb型慢性主动脉夹层动脉瘤患者,应考虑个体化的TAAAR或DTAR,而非默认采用微创一期修复。